Patent · US Expired

Lactobacillus reuteri to inhibit cryptosporidiosis in mammals

US6103227A · kind A · utility

15Cited by
2References
5Claims
0Family size

Inventors

Key dates

Filing dateJun 23, 1997
Grant dateAug 15, 2000
Priority date—
Expiry dateJun 23, 2017

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Cryptosporidium parvum (the cause of cryptosporidiosis) has become one of the most common enteropathogens causing diarrhea worldwide. Symptoms associated with cryptosporidiosis are very debilitating especially in the immunocompromised subject (e.g., AIDS patient). Clinical features include severe, chronic diarrhea, abdominal cramps, fatigue, weight loss, etc. which lead to increased health care costs and increased mortality. There is disclosed herein a method of inhibiting the severity of Cryptosporidium parvum infection by enterally administering a therapeutically effective amount of Lactobacillus reuteri.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.